Aster Capital Management DIFC Ltd Has $1.55 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Aster Capital Management DIFC Ltd grew its stake in shares of Stryker Co. (NYSE:SYK) by 177.0% during the 4th quarter, Holdings Channel reports. The firm owned 4,290 shares of the medical technology company’s stock after buying an additional 2,741 shares during the period. Stryker comprises about 0.6% of Aster Capital Management DIFC Ltd’s investment portfolio, making the stock its 23rd biggest position. Aster Capital Management DIFC Ltd’s holdings in Stryker were worth $1,545,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Chicago Capital LLC lifted its stake in Stryker by 3.1% in the fourth quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company’s stock valued at $70,228,000 after acquiring an additional 5,841 shares during the last quarter. Zhang Financial LLC lifted its stake in Stryker by 55.0% in the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock valued at $41,366,000 after purchasing an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA lifted its stake in Stryker by 5.0% in the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company’s stock valued at $10,521,000 after purchasing an additional 1,400 shares during the last quarter. Metis Global Partners LLC increased its position in Stryker by 10.2% during the fourth quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company’s stock worth $6,064,000 after buying an additional 1,561 shares during the last quarter. Finally, US Bancorp DE raised its stake in Stryker by 0.5% in the fourth quarter. US Bancorp DE now owns 182,825 shares of the medical technology company’s stock valued at $65,829,000 after buying an additional 976 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $346.14 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The company has a market cap of $132.12 billion, a price-to-earnings ratio of 44.61, a PEG ratio of 2.93 and a beta of 0.95. The stock has a fifty day moving average price of $381.69 and a 200-day moving average price of $374.30.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business earned $3.46 EPS. As a group, equities analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.97%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SYK shares. JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Truist Financial upped their price objective on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a report on Thursday, January 30th. Wells Fargo & Company raised their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Stifel Nicolaus upped their price target on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Finally, StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.